

ASX Market Announcement



Investor Webinar - Quarterly Business Update – June 2023

FY23 receipts up 29% YoY, Momentum Building on Commercial Tests of geneType

Melbourne, Australia, 3 August 2023: Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, "Company", "GTG"), a global leader in guideline-driven genomics-based testing in health, wellness and serious diseases, is pleased to invite shareholders and investors to attend a webinar where GTG's CEO will discuss the company's recent activities, achievements and top line milestones for the next 18 months.

Investor Webinar to be held 9 August 2023

GTG's CEO, Simon Morriss, and CFO & Company Secretary, Tony Di Pietro will host an investor webinar, to discuss the June 2023 Quarterly Activities Report and hold a Q&A session.

Date: Wednesday, 9 August 2023 (Tuesday, 8 August 2023, New York Time)

Time: 9.15am AEST (7.15pm New York Time).

Registration Link:

Participants are encouraged to register before the webinar using the details below:

https://us02web.zoom.us/webinar/register/WN_WWORhADCQl60OcZ1R0a2VA#/registration

Authorised for release by the Board of Genetic Technologies Limited

-END-

Enquiries

Investor Relations

Adrian Mulcahy

Automic Markets

M: +61 438 630 411

E: Adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genetype.com